Table 2 Summary characteristics of the proteomic clusters of the muscle-invasive bladder cancer neoadjuvant chemotherapy cohort
Pre-NAC (TUR) cluster | CC1-Luminal | CC2-Nuclear | CC3-Basal | CC4-Stroma-rich |
|---|---|---|---|---|
Number of patients in cluster (%) | 42 (39%) | 7 (7%) | 20 (19%) | 38 (35%) |
Clinical features | Female, T2+ | Small cell histology | Squamous, T3+ | T2+ |
Enriched gene sets | Mitochondrial, metabolic | mRNA processing | Cornification, antibody-mediated immune responses | Collagen, antibody-mediated immune responses |
MIBC transcriptomic subtype class concordance (%) | 95% | 57% | 94% | 11% |
Immune | Cold | Medium | Hot (Monocytes, T & B cells) | Hot (T & B cells) |
Stroma | Low | Low | Medium | High |
CR+PR Response to NAC (%) | 48% | 57% | 25% | 31% |
Post-NAC (RC) class switch using pre-NAC consensus cluster centroids (%) | 61% | 0% | 42% | 9.5% |
Median overall survival (months) | 113.5 | 66 | 15.6 | 52 |
Post-NAC (RC) cluster | PN-CC1 | PN-CC2 | PN-CC3 | PN-CC4 |
|---|---|---|---|---|
Number of patients in cluster (%) | 3 (6%) | 15 (27%) | 15 (27%) | 22 (40%) |
Enriched gene sets | mRNA processing and splicing | Keratinisation, RNA metabolism | ECM, antibody-mediate immune responses | Mitochondrial and metabolic processes |
Immune | Low | Hot | Medium | Low |
Stroma | Low | High | Medium | Low |
Recurrences at last follow-up (%) | 66% | 60% | 50% | 66% |
Median overall survival (months) | 3 | 9 | 26 | 32 |
Approved druggable targets | MTOR, PARP1, PARP2 | CD274, CTLA4 | CTLA4, CD274 | NECTIN4, ERBB2, EPCAM |
